We have been the DXA quality assurance site for many NIH-funded studies, CDC, and many more. Dr. Shepherd holds the patent that Hologic uses to measure body composition. Furthermore, we work closely with the manufacturers and maintain workstations for Hologic and GE systems with the rights to use that software on scans other than those at our site. He has also served as a past president of the ISCD and has either chaired or been a participant in all ISCD Position Development Conferences. Below you will find past and current QA studies conducted at SRL. For inquiries, please contact us for more information.
Dual-energy x-ray absorptiometry (DXA) scan analysis and quality control review for NHANES 2018-2022
In this study, we are working on NHANES 2018-2022 to review the existing procedures manuals and update as needed by detailing procedures for obtaining the DXA scans for the protocol, perform longitudinal calibrations and cross-calibrations, and provide correction factors, if necessary. Specifically, we will be looking at DXA scans of the hip, spine, VFA spine, and whole body acquired at NHANES mobile examination centers. This data, along with data from similar studies will be used to examine age, sex, and racial/ethnic differences during the life cycle and to explore the relationship between body composition and behavioral factors such as diet and physical activity.
IMPAACT 2009: Pharmacokinetics, Feasibility, Acceptability, and Safety of Oral Pre-Exposure Prophylaxis for Primary HIV Prevention during Pregnancy and Breast Feeding in Adolescents and Young Women and their Infants
IMPAACT 2010: Phase III Study of the Virologic Efficacy and Safety of Dolutegravir-Containing versus Efavirenz-Containing Antiretroviral Therapy Regimens in HIV-1-Infected Pregnant Women and their Infants
Our work with IMPAACT is divided between two studies: IMPAACT 2009 and IMPAACT 2010. IMPAACT 2009 is a study that evaluates daily oral Truvada PrEP in pregnant and lactating women. IMPAACT 2010 is a Phase III study of Virologic Efficacy and safety of Dolutegravir-containing versus Efavirenz-containing Antiretroviral therapy regimens in HIV-1-infected pregnant women and their infants. In both studies, our role is to monitor changes in bone mineral density (BMD), which will include central analysis of spine, femur, and whold body DXA scans. The IMPAACT 2009 study provides an important opportunity to study the effect of PrEP use and lactation on bone mass in young women who are yet to achieve peak bone mass. The IMPAACT 2010 study represents an important opportunity to learn more about the effects of the regimens on maternal and infant bone and renal outcomes.
Healthy Aging in Neighborhoods of Diversity across the Life Span (HANDLS)
The HANDLS study is a multidisciplinary, community-
based, prospective longitudinal epidemiologic study examining the influence of race and socioeconomic status (SES) on the development of age-related health disparities among socioeconomically diverse African Americans and whites in Baltimore. This study investigates whether health disparities develop or persist due to differences in SES, differences in
race, or their interaction. Similar to our work with NHANES, we are working on HANDLS to provide DXA analysis and quality control for their body composition and bone mineral density data. We are in the process of establishing procedures manuals and will review/update them as needed by detailing procedures for obtaining the DXA scans for the protocol, perform longitudinal calibrations and cross calibrations, and provide corrections factors, if necessary.
Extended use of NHANES Visceral Adiposity Cancer Risk Factors to GE Systems
The NHANES VAT measures will become the national reference data for VAT upon its release since there isn’t any other representative sample of VAT. However, the NHANES data was acquired on one make of DXA system, Hologic. VAT measures on Hologic DXA systems are substantially different than on GE systems, which complicate the pooling of VAT measures from different systems in multi-center clinical trials and make it difficult to compare VAT measures over time when a patient is scanned on different systems. Furthermore, with GE systems accounting for approximately 50% of the DXA clinical installation base, this means that half of the DXA users won’t be able to access the new NHANES VAT reference data. The objective of this study is to determine the relationship between Hologic and GE Lunar system for VAT measurements in children and adults, repost the NHANES VAT data in GE units, and provide cutoff points relevant for high risk of cancer and metabolic conditions.
Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY)
The TODAY study was a nationwide research study to compare the efficacy and safety of three interventions to treat adolescents and youth with type 2 diabetes. The primary outcome was time to treatment failure due to loss of glycemic control, defined as hemoglobin A1c >= 8% for 6 months. Secondary outcomes included measures of beta cell function and insulin resistance, body composition, nutrition, physical activity and aerobic fitness, cardiovascular risk factors, microvascular complications, quality of life, and psychological outcomes. The influence of individual and family behaviors on treatment response and the relative cost-effectiveness of the three treatment arms were also evaluated. This study has provided information fundamental to improving treatments and outcomes for youth with type 2 diabetes. Learn more.
Bone Mineral Density in Childhood Study
The BMDCS (2001-2011) offered an unprecedented opportunity to identify predictors of the timing and magnitude of peak bone mass, a major determinant of osteoporosis in later adulthood. BMDCS investigators provided reference curves for bone accrual and linear growth velocity that are comparable to the Centers for Disease Control and Prevention linear growth and weight gain curves for children and adolescents. The reference curves generated by this carefully executed study provided the gold standard for normal bone accrual for generations to come. The study’s results enable practitioners to identify the adverse effects that chronic illness has on bone. Additionally, the results have clarified the effects that the timing of pubertal onset have on bone density and linear growth, as well as the need for height adjustment for dual-energy X-ray absorptiometry results in children. Learn more.
BeMyKids Study: Bone Mineral Accretion in Young Children
Led by Dr. Heidi Kalkwarf, the BeMyKids study seeks to understand bone mineral accrual in children 1 to 5 years of age. A glaring deficit is the inability to evaluate bone health of children younger than 5 years due to lack of appropriate bone density reference data. This gap is problematic as there are numerous clinical conditions (e.g., neuromuscular disease, cancer, glucocorticoid treatment, extreme prematurity) that threaten bone health in this young age group. The findings from this study will facilitate medical care of children with chronic medical conditions that threaten bone health, and it will develop and validate novel methods for bone and body composition assessment in this age range. It will also add generalizable knowledge to enhance understanding of the growing skeleton, and its relationship to motor and somatic development. Learn more.
Safety Study of a Tenofovir-containing Drug Regimen for the Prevention of Mother-to-child Transmission of HIV and HBV – Tenofovir in Pregnancy (TiP) Study
The Tenofovir in Pregnancy (TiP) study was designed to test the safety of an antiretroviral combination containing TDF in pregnant women co-infected with HIV and HBV and their infants in Guangxi, China. The study’s objectives were to evaluate the renal, liver, and bone mineral density effects of TDF, administered from the second trimester of pregnancy, to women and their infants through a year postnatally. Learn more.
IMPAACT P1084s: Maternal and Infant Monitoring for Evidence of Toxicity Related to Tenofovir Exposure: The Bone and Kidney Health Substudy of PROMISE
P1084s is a nested, comparative substudy of HIV-1-infected women and their infants randomized in PROMISE (Promoting Maternal and Infant Survival Everywhere) to receive a maternal tenofovir-containing regimen or no maternal tenofovir-containing regimen during pregnancy or breastfeeding for prevention of mother-to-child transmission. The substudy was designed to examine bone, renal and growth outcomes of tenofovir exposure during pregnancy or during breastfeeding in 1077BF and 1077FF. Learn more.